X0306 4 2016-10-24 0 0001674416 CRISPR Therapeutics AG CRSP 0001252524 EMSTER KURT VON C/O CRISPR THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Shares 2016-10-24 4 C 0 2354050 0.00 A 2354050 I See Footnote Common Shares 2016-10-24 4 C 0 191764 0.00 A 2545814 I See Footnote Common Shares 2016-10-24 4 P 0 56000 14.00 A 2601814 I See Footnote Series A-3 Preferred Shares 0.00 2016-10-24 4 C 0 2354050 0.00 D Common Shares 2354050 0 I See Footnote Series B Preferred Shares 0.00 2016-10-24 4 C 0 191764 0.00 D Common Shares 191764 0 I See Footnote These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. /s/ Kurt von Emster 2017-02-10